Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia.
Department of Pharmacy, Universitas Airlangga Hospital, Surabaya, Indonesia.
J Oncol Pharm Pract. 2024 Sep;30(6):1096-1100. doi: 10.1177/10781552241261250. Epub 2024 Jun 11.
Cancer is among the leading causes of death globally, posing a significant economic burden on the healthcare sector. Among other types of cancer in Indonesia, non-Hodgkin lymphoma (NHL) ranks fifth in terms of prevalence. Chemotherapy for NHL patients is funded by a national health insurance scheme through the National Healthcare Insurance and Social Security/Jaminan Kesehatan Nasional (JKN).
This study aimed to analyze cost burden of chemotherapy for JKN patients with NHL.
A retrospective cross-sectional observational study was conducted among NHL patients receiving chemotherapy at a hospital in East Java, Indonesia in 2021. Data were collected from medical record documents and a total of 44 patient visits were recorded in this study.
The result showed that patient visits were dominated by females (55%), a significant proportion were aged 31 to 40 years (32%), and the majority were JKN participants in the Contribution Assistance Recipients/Penerima Bantuan Iuran (PBI) category (64%). The most chemotherapy regimen given was R-CHOP (68%) and the mean total cost for NHL patients was Indonesian Rupiah (IDR) 5,178,146. The highest mean cost burden was on chemotherapy drugs with a value of IDR 6,333,315. Based on the regimen, the highest cost burden was R-CHOP-Bleo with a mean cost of IDR 8,764,091.
Based on the results, the highest cost burden for chemotherapy among JKN patients with NHL in Indonesia was attributed to R-CHOP-Bleo regimen with a mean of IDR 8,764,091.
癌症是全球主要死因之一，给医疗保健部门带来了巨大的经济负担。在印度尼西亚的其他癌症类型中，非霍奇金淋巴瘤（NHL）的发病率位居第五。NHL 患者的化疗由国家医疗保险计划通过国家医疗保险和社会保障/国民健康保险（JKN）提供资金。
本研究旨在分析 JKN 患者 NHL 化疗的费用负担。
本研究是一项 2021 年在印度尼西亚东爪哇一家医院进行的 NHL 接受化疗的患者的回顾性横断面观察性研究。数据来自病历文件，本研究共记录了 44 例患者就诊。
结果显示，就诊患者以女性（55%）为主，相当一部分患者年龄在 31 至 40 岁之间（32%），大多数是 JKN 参与者中的缴费援助接受者/受助缴费者（PBI）类别（64%）。给予的最常见化疗方案是 R-CHOP（68%），NHL 患者的平均总费用为印度尼西亚卢比（IDR）5178146。化疗药物的平均费用最高，为 IDR 6333315。按方案计算，R-CHOP-Bleo 的费用负担最高，平均费用为 IDR 8764091。
根据研究结果，印度尼西亚 JKN 患者 NHL 化疗的最高费用负担归因于 R-CHOP-Bleo 方案，平均费用为 IDR 8764091。
